BELANO Medical - The Micro­biotics Company
BELANO Medical
The Micro­biotics Company

Press releases

Novel bioactive from Lactobacillus brevis DSM17250 to stimulate the growth of Staphylococcus epidermidis: a pilot study 

Commensal skin micro­biota plays an important role in both influ­encing the immune response of the skin and acting as a barrier against coloni­sation of poten­tially patho­genic micro­or­ga­nisms and overgrowth of oppor­tu­nistic pathogens. Staphy­lo­coccus epider­midis is a key consti­tuent of the normal micro­biota on human skin. It balances the inflammatory response after skin injury and produces antimi­crobial molecules that selec­tively inhibit skin pathogens. C. Holz,

Novel bioactive from Lacto­ba­c­illus brevis DSM17250 to stimulate the growth of Staphy­lo­coccus epider­midis: a pilot study mehr lesen

read more 

European Biotechnology - The problem starts in your gut 

Evidence that what we eat and how we live affects our health is becoming greater.The bacteria, who have been colonising our skin and gut since our very beginning, seem to play an important role as sensors for environ­mental triggers of chronic diseases of civili­sation. Since it became clear that restoring the balance of the micro­biome cures 90% of people with Clostridium dificile infec­tions, food

European Biotech­nology - The problem starts in your gut mehr lesen

read more 

Interview with Christine Lang : Bioeconomy drives Resource Efficency 

“Bioeconomy can no longer be seen only as the repla­cement for fossil raw materials. It is based on the combi­nation of renewable resources and innovation to drive resource efficiency and Green Growth.” To say this – in this interview with Renewable Matter – is Christine Lang, chair­woman of the German Bioeconomy Council. With Lang we talk about the bioeconomy in Germany, the Federal strategy,

Interview with Christine Lang : Bioeconomy drives Resource Efficency mehr lesen

read more 

Significant Reduction in Helicobacter pylori Load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot Study. 

Reducing the amount of Helico­bacter pylori in the stomach by selective bacterial–bacterial cell inter­action was sought as an effective and novel method for combating the stomach pathogen. Lacto­ba­c­illus reuteri DSM17648 was identified as a highly specific binding antagonist to H. pylori among more than 700 wild-type strains of Lacto­ba­c­illus species. C. Holz, A. Busjahn, H. Mehling, S. Arya, M. Boettner, H. Habibi, C. Lang

Signi­ficant Reduction in Helico­bacter pylori Load in Humans with Non-viable Lacto­ba­c­illus reuteri DSM17648: A Pilot Study. mehr lesen

read more 
May 2022
Scroll to Top